.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,749,488

« Back to Dashboard

Details for Patent: 7,749,488

Title:Pharmaceutical foam
Abstract: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
Inventor(s): Abram; Albert Zorko (Wantirna, AU), Fuchshuber; Lilian (Narre Warren, AU)
Assignee: Stiefel Research Australia Pty Ltd (Rowville, Victoria, AT)
Filing Date:Feb 07, 2006
Application Number:11/349,820
Claims:1. A topical delivery foam composition in a pressurized container, said composition comprising: benzoyl peroxide and clindamycin or a salt or ester thereof; a quick-breaking foaming agent comprising: a) water present between about 80% to about 95% w/w, b) a surfactant, c) a pH adjusting agent, and d) xanthan gum, wherein the quick-breaking foaming agent contains about 0% emollient and contains about 0% of a C.sub.1-C.sub.6 alcohol; and an aerosol propellant selected from the group consisting of a hydrocarbon, a chlorofluorocarbon, dimethyl ether, hydrofluorocarbons and a mixture thereof, wherein said composition is a quick-breaking foam after release from said container, and the pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to between about 4.0 to about 6.5.

2. The topical delivery foam composition of claim 1, wherein said clindamycin is clindamycin phosphate.

3. The topical delivery foam composition of claim 1, wherein said surfactant is selected from the group consisting of a block co-polymers, fatty acid ethoxylates, fatty alcohol ethoxylates, polysorbates and glycerol ester ethoxylates.

4. A topical delivery foam composition in a pressurized container, said composition consisting essentially of: benzoyl peroxide and clindamycin or a salt or ester thereof; a quick-breaking foaming agent comprising: a) water present between about 80% to about 95% w/w, b) a surfactant, c) a pH adjusting agents, and d) xanthan gum, wherein the quick-breaking foaming agent contains about 0% emollient and contains about 0% of a C.sub.1-C.sub.6 alcohol; and an aerosol propellant selected from the group consisting of a hydrocarbon, a chlorofluorocarbon, dimethyl ether, hydrofluorocarbons and a mixture thereof, wherein said composition is a quick-breaking foam after release from said container, and the pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to between about 4.0 to about 6.5.

5. The topical delivery foam composition of claim 4, wherein said clindamycin is clindamycin phosphate.

6. The topical delivery foam composition of claim 4, wherein said surfactant is selected from the group consisting of a block co-polymer, fatty acid ethoxylates, fatty alcohol ethoxylates, polysorbates and glycerol ester ethoxylates.

7. The topical delivery foam composition of claim 3, wherein the surfactant is a block copolymer.

8. The topical delivery foam composition of claim 7, wherein the block copolymer is a poloxamer.

9. The topical delivery foam composition of claim 3, wherein the surfactant is a fatty alcohol ethoxylate.

10. The topical delivery foam composition of claim 1, wherein the surfactant is present in an amount of from about 0.1% to about 10% w/w.

11. The topical delivery foam composition of claim 10, wherein the surfactant is present in an amount of from about 0.1% to about 6% w/w.

12. The topical delivery foam composition of claim 1, wherein the pH adjusting agent is a buffer.

13. The topical delivery foam composition of claim 12, wherein the buffer is selected from the group consisting of citrate/citric acid, acetate/acetic acid, phosphate/phosphoric acid, formate/formic acid, propionate/propionic acid, lactate/lactic acid, carbonate/carbonic acid and ammonium/ammonia buffer.

14. The topical delivery foam composition of claim 13, wherein the buffer is citrate/citric acid.

15. The topical delivery foam composition of claim 6, wherein the surfactant is a block copolymer.

16. The topical delivery foam composition of claim 15, wherein the block copolymer is a poloxamer.

17. The topical delivery foam composition of claim 6, wherein the surfactant is a fatty alcohol ethoxylate.

18. The topical delivery foam composition of claim 4, wherein the surfactant is present in an amount of from about 0.1% to about 10% w/w.

19. The topical delivery foam composition of claim 18, wherein the surfactant is present in an amount of from about 0.1% to about 6% w/w.

20. The topical delivery foam composition of claim 4, wherein the pH adjusting agent is a buffer.

21. The topical delivery foam composition of claim 20, wherein the buffer is selected from the group consisting of citrate/citric acid, acetate/acetic acid, phosphate/phosphoric acid, formate/formic acid, propionate/propionic acid, lactate/lactic acid, carbonate/carbonic acid and ammonium/ammonia buffer.

22. The topical delivery foam composition of claim 21, wherein the buffer is citrate/citric acid.

23. A topical delivery foam composition in a pressurized container, said composition comprising: benzoyl peroxide and clindamycin or a salt or ester thereof; a quick-breaking foaming agent comprising; a) water present between about 80% to about 95% w/w, b) a surfactant, and c) a pH adjusting agent, wherein the quick-breaking foaming agent contains about 0% emollient and contains about 0% of a C1-C6 alcohol; and an aerosol propellant selected from the group consisting of a hydrocarbon, a chlorofluorocarbon, dimethyl ether, hydrofluorocarbons and a mixture thereof, wherein said composition is a quick-breaking foam after release from said container, and the pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to between about 4.0 to about 6.5.

24. The topical delivery foam composition of claim 23, wherein the surfactant is selected from the group consisting of a block copolymer, fatty acid ethoxylates, fatty alcohol ethoxylates, polysorbates and glycerol ester ethoxylates.

25. The topical delivery foam composition of claim 23, wherein the pH adjusting agent is selected from the group consisting of a base and a buffer.

26. The topical delivery foam composition of claim 25, wherein the pH adjusting agent is a buffer.

27. The topical delivery foam composition of claim 23, wherein the composition further comprises xanthan gum.

28. The topical delivery foam composition of claim 26, wherein the composition further comprises xanthan gum.

29. The topical delivery foam composition of claim 24, wherein the surfactant is a block copolymer.

30. The topical delivery foam composition of claim 29, wherein the block copolymer is a poloxamer.

31. The topical delivery foam composition of claim 24, wherein the surfactant is a fatty alcohol ethoxylate.

32. The topical delivery foam composition of claim 26, wherein the buffer is selected from the group consisting of citrate/citric acid, acetate/acetic acid, phosphate/phosphoric acid, formate/formic acid, propionate/propionic acid, lactate/lactic acid, carbonate/carbonic acid and ammonium/ammonia buffer.

33. The topical delivery foam composition of claim 32, wherein the buffer is citrate/citric acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc